Benzinga · Oct 13, 2026
TD Cowen Maintains Hold on Quanterix, Raises Price Target to $3.5
TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and raises the price target from $3 to $3.5.
QT
NASDAQ · QTRX
Quanterix Corporation
Healthcare · Medical - Devices
$2.86
Up+$0.02 (+0.70%)
Updated Oct 25, 2026, 10:09 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 352.9M
- P/E ratio
- -4.17
- Dividend yield
- 0.00%
- 52-week range
- $2.15 – $8.77
- Volume
- 349.8K
- Avg. volume
- 639.37K
Price performance · QTRX
QTRX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
QTRX closed at $2.86 after 20 trading sessions, down 18.75% for the selected period.
- Last close
- $2.86
- Period change
- -18.75%
- Period low
- $2.72
- Period high
- $3.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $2.82 | $2.88 | $2.71 | $2.86 | 349.8K |
| Oct 22, 2026 | $2.74 | $2.895 | $2.71 | $2.84 | 496.29K |
| Oct 21, 2026 | $2.71 | $2.815 | $2.675 | $2.79 | 525.25K |
| Oct 20, 2026 | $2.77 | $2.845 | $2.71 | $2.72 | 536.49K |
| Oct 19, 2026 | $2.87 | $2.93 | $2.72 | $2.77 | 430.15K |
| Oct 16, 2026 | $3.07 | $3.07 | $2.835 | $2.87 | 323.24K |
| Oct 15, 2026 | $3.05 | $3.105 | $2.92 | $3.07 | 291.06K |
| Oct 14, 2026 | $3.10 | $3.23 | $3.05 | $3.06 | 342.29K |
| Oct 13, 2026 | $3.17 | $3.335 | $3.11 | $3.15 | 749.92K |
| Oct 12, 2026 | $3.28 | $3.35 | $3.07 | $3.16 | 562.79K |
| Oct 9, 2026 | $3.22 | $3.445 | $3.20 | $3.28 | 282.66K |
| Oct 8, 2026 | $3.25 | $3.25 | $3.0613 | $3.21 | 607.39K |
| Oct 7, 2026 | $3.40 | $3.55 | $3.31 | $3.325 | 493.64K |
| Oct 6, 2026 | $3.83 | $3.98 | $3.42 | $3.44 | 606.57K |
| Oct 5, 2026 | $3.66 | $3.8968 | $3.62 | $3.81 | 1.03M |
| Oct 2, 2026 | $3.44 | $3.69 | $3.44 | $3.64 | 590.81K |
| Oct 1, 2026 | $3.72 | $3.72 | $3.375 | $3.41 | 629.49K |
| Sep 30, 2026 | $3.67 | $3.72 | $3.59 | $3.71 | 545.39K |
| Sep 29, 2026 | $3.52 | $3.71 | $3.454 | $3.67 | 623.45K |
| Sep 28, 2026 | $3.25 | $3.6735 | $3.23 | $3.52 | 1.04M |
Latest QTRX news
The latest Smart Investors Daily articles mentioning QTRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
QTRX research
Overview
Company profile and research snapshot.
Company profile
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Hold | — |
| Aug 17, 2026 | Canaccord Genuity | Hold | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| May 7, 2026 | TD Cowen | Hold | — |
| Apr 20, 2026 | Canaccord Genuity | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 7, 2026
ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research
ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology.
Yahoo · Oct 7, 2026
/C O R R E C T I O N -- ALZpath, Inc./
ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology.
Yahoo · Oct 7, 2026
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
BILLERICA, Mass. & BEIJING, October 07, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
